Osborn Williams & Donohoe’s DexCom DXCM Stock Holding History

Osborn Williams & Donohoe’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-400	Closed	-$12K	–	405
2019 Q1	$12K	Buy	+400	New	+$14.1K	﹤0.01%	605

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Osborn Williams & Donohoe's DXCM Position: Q2 2019 in Review

Osborn Williams & Donohoe sold out of DexCom (DXCM) in Q2 2019, closing a stake of 400 shares — an estimated $12K sold.

Osborn Williams & Donohoe first reported a position in DXCM in Q1 2019 and held it in 1 quarter. The position peaked at $12K in Q1 2019. 418 funds tracked by Wall St. Rank hold DXCM as of Q2 2019.

Osborn Williams & Donohoe reported no remaining DexCom position as of Q2 2019 after selling out during the quarter.
Osborn Williams & Donohoe sold 400 DexCom shares in Q2 2019, an estimated $12K.
Osborn Williams & Donohoe first reported a position in DexCom in Q1 2019 and held it in 1 quarter.
Osborn Williams & Donohoe's DexCom position peaked at $12K in Q1 2019.
418 funds tracked by Wall St. Rank held DexCom as of Q2 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q2 2019, filed 26 Jul 2019.